Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed (2018 - 2026)

Kiniksa Pharmaceuticals International's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 14.61% for Q1 2026.

• Quarterly Return on Capital Employed rose 1782.0% year-over-year to 14.61% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14.61% (up 1782.0% YoY) and the FY2025 annual result came in at 14.49%, up 2456.0% from the prior year.
• Return on Capital Employed was 14.61% for Q1 2026 at Kiniksa Pharmaceuticals International, up from 12.9% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 14.61% in Q1 2026 and bottomed at 71.98% in Q1 2022.
• A 5-year average of 7.95% and a median of 4.47% in 2023 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 8147 bps — and 2024, when it tumbled 1531 bps.
• Kiniksa Pharmaceuticals International's Return on Capital Employed stood at 2.37% in 2022, then plunged by 341 bps to 5.71% in 2023, then tumbled by 71 bps to 9.76% in 2024, then jumped by 232 bps to 12.9% in 2025, then rose by 13 bps to 14.61% in 2026.
• Business Quant data shows KNSA's Return on Capital Employed at 14.61% in Q1 2026, 12.9% in Q4 2025, and 6.78% in Q3 2025.